secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001534120-26-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics estimates $98M cash as of Dec 31, 2025 in preliminary update
-------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and short-term investments of ~$98M as of December 31, 2025.
- Estimate is unaudited and preliminary; actual year-end results may differ materially.
- Company also posted an updated investor presentation highlighting its IL-1β pipeline.
- Full financial results to be reported in the 2025 Form 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000003/0001534120-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000003/avtx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer